MX2020012799A - Composicion y metodo para tratar el cancer asociado con mutacion del egfr. - Google Patents

Composicion y metodo para tratar el cancer asociado con mutacion del egfr.

Info

Publication number
MX2020012799A
MX2020012799A MX2020012799A MX2020012799A MX2020012799A MX 2020012799 A MX2020012799 A MX 2020012799A MX 2020012799 A MX2020012799 A MX 2020012799A MX 2020012799 A MX2020012799 A MX 2020012799A MX 2020012799 A MX2020012799 A MX 2020012799A
Authority
MX
Mexico
Prior art keywords
composition
treating cancer
cancer associated
egfr mutation
egfr
Prior art date
Application number
MX2020012799A
Other languages
English (en)
Inventor
Lan Huang
George Kenneth Lloyd
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Publication of MX2020012799A publication Critical patent/MX2020012799A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

En este documento se divulgan la plinabulina y su uso para tratar un cáncer o tumor caracterizado por la expresión de una forma mutante de una proteína del receptor del factor de crecimiento epidérmico (EGFR), que comprende administrar plinabulina a un sujeto que lo necesite.
MX2020012799A 2018-06-01 2019-05-30 Composicion y metodo para tratar el cancer asociado con mutacion del egfr. MX2020012799A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862679619P 2018-06-01 2018-06-01
PCT/US2019/034726 WO2019232257A1 (en) 2018-06-01 2019-05-30 Composition and method of treating cancer associated with egfr mutation

Publications (1)

Publication Number Publication Date
MX2020012799A true MX2020012799A (es) 2021-03-25

Family

ID=68696755

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012799A MX2020012799A (es) 2018-06-01 2019-05-30 Composicion y metodo para tratar el cancer asociado con mutacion del egfr.

Country Status (9)

Country Link
US (1) US20210161888A1 (es)
EP (1) EP3801524A4 (es)
JP (1) JP2021525768A (es)
KR (1) KR20210015875A (es)
CN (1) CN112543636B (es)
AU (1) AU2019278886A1 (es)
CA (1) CA3101612A1 (es)
MX (1) MX2020012799A (es)
WO (1) WO2019232257A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201707127VA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
RU2753543C1 (ru) 2016-02-08 2021-08-17 Бейондспринг Фармасьютикалс, Инк. Композиции, содержащие тукаресол или его аналоги
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
CA3089226A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CA3233721A1 (en) * 2021-10-03 2023-04-06 Sa XIAO Methods of treating cancer and the pharmaceutical compositions thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302721B2 (en) * 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
EP2477985B1 (en) * 2009-09-15 2018-11-07 BlueLink Pharmaceuticals, Inc. Crlx101 for use in the treatment of cancer
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
PT2958943T (pt) * 2013-02-20 2019-12-17 Novartis Ag Tratamento do cancro usando recetor de antigénios quiméricos anti-egfrviii humanizados
NZ734256A (en) * 2015-02-12 2019-02-22 Beyondspring Pharmaceuticals Inc Use of plinabulin in combination with immune checkpoint inhibitors
SG11201707127VA (en) * 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
US20200129504A1 (en) * 2017-03-13 2020-04-30 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof

Also Published As

Publication number Publication date
EP3801524A4 (en) 2022-03-02
JP2021525768A (ja) 2021-09-27
CN112543636B (zh) 2024-03-01
AU2019278886A1 (en) 2020-12-24
CA3101612A1 (en) 2019-12-05
WO2019232257A1 (en) 2019-12-05
KR20210015875A (ko) 2021-02-10
US20210161888A1 (en) 2021-06-03
EP3801524A1 (en) 2021-04-14
CN112543636A (zh) 2021-03-23

Similar Documents

Publication Publication Date Title
MX2020012799A (es) Composicion y metodo para tratar el cancer asociado con mutacion del egfr.
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
MX2020010458A (es) Conjugados de camptotecina-peptido.
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
MY190034A (en) Method of treating cancer associated with a ras mutation
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
PH12014502437A1 (en) Anti-egfr antibodies and uses threof
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
MX2019010382A (es) Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva.
MX2022002682A (es) Anticuerpos anti-cd73.
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
PH12018502549A1 (en) Pharmaceutical combinations
MX2021001508A (es) Proteínas de unión multiespecífica que se unen a her2, nkg2d y cd16 y métodos de uso.
MX2021012335A (es) Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
MX2021005761A (es) Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados.
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
MX2022003466A (es) Interrupción de los tejidos tumorales al dirigir la proteína de activación de fibroblastos (fap).
MX2020008613A (es) Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer.
PH12021551276A1 (en) Combination therapy for the treatment of cancer
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
PH12020551495A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
NZ625758A (en) Method for treating breast cancer